 |
|
hypoxia-activated prodrug TH-302
An hypoxia-activated prodrug consisting of an indazole-based tubulin inhibitor conjugated with a hypoxic activator, such as a substituted nitroimidazole, with potential antineoplastic activity. When the hypoxia activator of hypoxia-activated prodrug TH-302 is activated by low oxygen concentrations in the hypoxic regions of tumors, the indazole-based tubulin inhibitor is released, which may result in the inhibition of tubulin polymerization in tumor cells and tumor cell mitotic arrest and death. Normoxic tissues are spared due to the hypoxia-specific release of the cyctotoxic moiety. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Abbreviation: | | HAP TH-302 | | | | Code name: | | TH-302 | | |
|
|
